Browsing by Author "Schultz, K. R."

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Biomarkers in chronic graft-versus-host disease: quo vadis?
    (Springer Nature, 2018-07) Wolff, D.; Greinix, H.; Lee, S.J.; Gooley, T.; Paczesny, Sophie; Pavletic, S.; Hakim, F.; Malard, F.; Jagasia, M.; Lawitschka, A.; Hansen, J.A.; Pulanic, D.; Holler, E.; Dickinson, A.; Edinger, M.; Sarantopoulos, S.; Schultz, K. R.; Pediatrics, School of Medicine
    Biomarkers are increasingly used for diagnosis and treatment of transplant-related complications including the first biomarker-driven interventional trials of acute graft-versus-host disease (GvHD). In contrast, the development of biomarkers of chronic GvHD (cGvHD) has lagged behind due to a broader variety of manifestations, overlap with acute GvHD, a greater variation in time to onset and maximum severity, and lack of sufficient patient numbers within prospective trials. An international workshop organized by a North-American and European consortium was held in Marseille in March 2017 with the goal to discuss strategies for future biomarker development to guide cGvHD therapy. As a result of this meeting, two areas were prioritized: the development of prognostic biomarkers for subsequent onset of moderate/severe cGvHD, and in parallel, the development of qualified clinical-grade assays for biomarker quantification. The most promising prognostic serum biomarkers are CXCL9, ST2, matrix metalloproteinase-3, osteopontin, CXCL10, CXCL11, and CD163. Urine-proteomics and cellular subsets (CD4+ T-cell subsets, NK cell subsets, and CD19+CD21low B cells) represent additional potential prognostic biomarkers of cGvHD. A joint effort is required to verify the results of numerous exploratory trials before any of the potential candidates is ready for validation and subsequent clinical application.